The regulatory environment governing the botanical Mitragyna speciosa (commonly known as kratom) and its primary alkaloids, mitragynine and 7-hydroxymitragynine (7-OH), has become the epicenter of a profound jurisdictional and political conflict in the United States. As the domestic market for non-pharmaceutical, botanical pain management alternatives has expanded, a highly coordinated, multi-jurisdictional effort has emerged to classify these compounds as Schedule I substances under the Controlled Substances Act (CSA) and equivalent state statutes. A forensic examination of the administrative actions, campaign finance networks, and lobbying activities driving this regulatory push reveals a complex political economy characterized by structural biases, severe conflicts of interest, and the aggressive deployment of executive emergency powers to circumvent traditional legislative deliberation.
At the federal echelon, the DEA and FDA have initiated aggressive, bifurcated scheduling actions targeting concentrated 7-OH and its highly potent synthetic derivatives. Simultaneously, a high-level congressional investigation has exposed alleged ethical breaches within the executive branch, wherein cabinet-level officials possessing direct, million-dollar financial stakes in specific kratom enterprises have, according to the investigation, actively utilized their governmental authority to lobby for the prohibition of competing products. These federal actions are further complicated by the influence of the pharmaceutical and tobacco lobbies, which seek to maintain market dominance over the lucrative spaces of analgesia and addiction mitigation.
At the state level, Ohio serves as the premier operational case study in regulatory capture and administrative overreach. Between the fourth quarter of 2025 and the summer of 2026, Governor Mike DeWine and the gubernatorially appointed Ohio Board of Pharmacy (OBP) engaged in a sustained campaign to criminalize both synthetic kratom derivatives and the natural botanical leaf via emergency administrative rules — concurrently with the administration's approval of substantial, multi-million-dollar tax incentives for traditional, corporate pharmaceutical manufacturers. The OBP's composition — consisting entirely of professionals whose livelihoods depend on the conventional, FDA-approved pharmaceutical supply chain — presents a structural conflict of interest when regulating an over-the-counter botanical competitor. The executive branch's attempt to unilaterally schedule these compounds provoked a significant constitutional clash with the Ohio General Assembly, culminating in formal rebukes from the Joint Committee on Agency Rule Review (JCARR) as lawmakers attempted to implement their own statutory, industry-compromise regulatory frameworks.
To accurately assess the political and regulatory mechanisms deployed against kratom, it is necessary to delineate the pharmacological distinctions that regulators and lobbyists exploit to craft policy. Kratom is a tropical evergreen tree indigenous to Southeast Asia, where it has a long history of traditional use. The botanical leaf contains numerous indole alkaloids, the most prominent being mitragynine, which functions as a partial agonist at the mu-opioid receptor. In its natural, vegetative state, the leaf also contains trace amounts of 7-hydroxymitragynine (7-OH), an oxidized derivative of mitragynine that is pharmacologically significantly more potent.
The modern regulatory crisis was catalyzed not by the traditional botanical leaf, but by the rapid commercialization of highly concentrated, standardized, and semi-synthetic 7-OH isolates. Commercial manufacturers began producing products where the 7-OH concentration vastly exceeds the natural ratios found in the plant, marketing them in convenience stores and vape shops in the form of flavored chewable tablets, gummies, and liquid shots.
The regulatory apparatus seized upon the proliferation of these isolates, observing that they display a rapid onset of action, a duration of effect lasting several hours, and a significantly higher potential for toxicity and dependency than the raw botanical material. Furthermore, manufacturers began synthesizing entirely novel derivatives that do not naturally occur in the kratom plant, such as mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16, engineering them specifically to enhance opioid receptor binding affinity and potency. Preclinical data indicates that MP is approximately 100 times more potent than baseline mitragynine, while MGM-15 and MGM-16 exhibit binding affinities rendering them 50 to 240 times more potent than classical morphine.
None of which says lethal. These are binding-affinity numbers, and binding affinity is not a body count. When regulators recite "240× morphine" they are citing the one axis on which these compounds look maximally scary while omitting the axis that determines whether users die. The contrast is stark enough to chart:
The 1,200% poison-center call increase officials cite (258 → 3,434) sounds alarming until you notice what it counts: calls, including curiosity calls driven by the press releases themselves — not fatalities, not hospitalizations. For context, in 2021 poison centers logged 1,524 kratom case mentions against 282,880 for pharmaceutical and illegal opioids — a ratio of 1:186.
The emergence of these synthetic derivatives provided federal and state agencies with the requisite "imminent hazard" narrative to justify the deployment of emergency scheduling powers. However, as the subsequent analysis demonstrates, the regulatory response extended far beyond targeted synthetic prohibition, evolving into a broader campaign of market elimination deeply influenced by corporate lobbying and political financing.
The federal government's approach to regulating the alkaloids of Mitragyna speciosa has historically been defined by bureaucratic hesitation, punctuated by aggressive, highly publicized enforcement attempts that often retreat in the face of public backlash. In August 2016, the DEA filed a notice of intent to temporarily place both mitragynine and 7-OH into Schedule I of the CSA. This action triggered an unprecedented public response, generating widespread demonstrations, formal petitions, and bipartisan congressional intervention, ultimately forcing the DEA to withdraw its notice in October 2016 — a rare administrative defeat for the agency.
However, the 2025–2026 proliferation of standardized 7-OH isolates and synthetic fluoro-derivatives provided the DEA and the FDA with renewed justification to intervene.
On July 1, 2026, the DEA, operating in conjunction with scientific recommendations from HHS, published two Notices of Intent (NOI) in the Federal Register, outlining a bifurcated regulatory strategy.
| Directive | Targeted compounds | Threshold / specs | Mechanism |
|---|---|---|---|
| NOI 1 (Threshold) | 7-hydroxymitragynine (7-OH) | > 0.05% by dry weight in botanical material; or > 1.00 mg per article in synthetic/processed products | Proposed temporary Schedule I placement; subject to public comment |
| NOI 2 (Absolute) | Mitragynine pseudoindoxyl (MP), MGM-15, MGM-16 | No threshold — any quantity | Emergency temporary Schedule I placement |
The structural logic of NOI 1 is particularly indicative of modern regulatory statecraft. By establishing a strict threshold of 0.05% by dry weight for 7-OH, the DEA strategically designed the rule to theoretically protect raw botanical kratom leaf — which naturally contains trace amounts of 7-OH below this limit — while effectively criminalizing the entire commercial market for concentrated 7-OH extracts, which typically contain doses ranging from 10 mg to 50 mg per retail unit.
Simultaneously, NOI 2 targeted the purely synthetic derivatives that have zero botanical baseline. By August 25, 2026, the Department of Justice formally executed the emergency scheduling of MP, MGM-15, and MGM-16, placing them into Schedule I for an initial period of two years, with the possibility of a one-year extension. This rapid execution allowed federal authorities to bypass the permanent rulemaking process by invoking an "imminent hazard to public safety."
Notably, the threshold-based scheduling of 7-OH itself remained pending well beyond its earliest possible implementation date of August 5, 2026, following a public Request for Information (RFI) initiated by the Office of the Assistant Secretary for Health (OASH) that generated over 32,000 comments. The delay in finalizing the 7-OH ban highlights internal friction within the executive branch — a friction exacerbated by profound conflicts of interest at the cabinet level.
The integrity of the federal push to schedule kratom derivatives cannot be evaluated merely as an objective exercise in public health policy. In 2026, the Senate Finance Committee's ranking member, Ron Wyden, launched a formal, highly visible investigation into the administration regarding alleged ethical breaches favoring specific entities within the kratom and tobacco industries. It bears repeating: this is an investigation by the ranking member, not the chairman — no subpoena power, and recipients of the letters were under no legal obligation to respond. The findings referenced below are the probe's allegations and cited reporting, not adjudicated findings.
Mullin / Botanic Tonics corroborated — According to the Wyden investigation and OGE disclosure reporting, Secretary of Homeland Security Markwayne Mullin held a direct, personal financial stake — reportedly valued between $500,000 and $1 million — in Botanic Tonics, a prominent Oklahoma-based kratom company (maker of "Feel Free"). Reporting further indicates Mullin advocated for strict federal restrictions on the synthetic competitors to his own company's products. A cabinet-level official weaponizing the coercive power of the state to eliminate market competition for his private financial assets is a textbook manifestation of corruption and regulatory capture: lobbying for the DEA and FDA to destroy the synthetic 7-OH market while preserving the specific botanical formulations sold by Botanic Tonics.
The investigation also scrutinized communications and back-channel coordination between HHS Secretary Robert F. Kennedy Jr., Botanic Tonics CEO Jerry Ross, and prominent industry lobbyists representing Big Tobacco, including David Waterfield, President and CEO of Reynolds American. Reporting on the probe's money trail: Botanic Tonics contributed $1 million to MAHA PAC — roughly 44% of the PAC's entire fundraising — during the push to ban its synthetic competitors; Ross donated $162K to Kennedy's campaign after it suspended; Reynolds gave $5M to MAGA Inc., a Reynolds executive lunched with President Trump on May 2, and flavored-vape protections were rolled back May 8. That timeline is the heart of Wyden's case.
Separately, the DOJ dropped its case against Botanic Tonics in December 2025 corroborated — after having seized roughly 250,000 bottles following an FDA inspection, as reported by Issues & Insights and Signal Ohio (which also documents Ohio's sales scale: ~59,000 Feel Free bottles/day).
The politicization of these public health directives generated severe internal dissent within the administration. The resignation of former FDA Commissioner Marty Makary serves as a critical inflection point. Makary resigned citing executive interference, the overriding of scientific consensus by special-interest lobbying, and cabinet-level conflicts of interest that prioritized corporate enrichment over coherent public health policy — specifically noting the administration's push to weaken restrictions on favored industries, such as flavored vaping and specific kratom companies, while selectively enforcing crackdowns on others.
Independent consumer advocacy groups, such as Public Citizen, echoed these concerns, releasing reports characterizing the administration's actions as a "fake crackdown" — publicly banning specific 7-OH thresholds while intentionally leaving highly profitable, dangerous products on store shelves to protect the financial interests of favored corporate entities.
What the pharmaceutical-lobbying record actually shows. The report this analysis draws from asserted the industry spent "over $100 million on federal lobbying in Q2 2025 alone" — a figure we could not trace to any citation and do not repeat as fact. But the verified record makes the same point more honestly: pharma doesn't need a sudden burst of spending, because its baseline is permanently enormous.
The direction of pharmaceutical-industry pressure against botanical analgesics competing with buprenorphine/naloxone and other prescription therapies is well documented in lobbying-records reporting — and against that ~$390M/yr baseline, note the asymmetry of the scheduling response: competitors of the most-lobbied industry in America face emergency prohibition while the industry's own opioid products remain on formularies.
While the federal government navigated corruption scandals and threshold-based scheduling, Ohio emerged as the vanguard for total prohibition — a premier case study in how state-level executive powers can be leveraged to achieve the objectives of entrenched commercial interests. The political machinery driving Ohio's kratom ban illustrates the strategic use of emergency administrative authority to circumvent legislative oversight.
In August 2025, Governor Mike DeWine publicly directed the Ohio Board of Pharmacy (OBP) to classify all natural and synthetic kratom compounds as Schedule I illegal drugs. Citing poison control data and labeling the botanical an "imminent public health risk," DeWine demanded the immediate removal of all kratom-related merchandise from retail establishments. On December 11, 2025, DeWine escalated, specifically targeting synthetic derivatives such as 7-OH and mitragynine pseudoindoxyl, instructing the OBP to implement an immediate ban via the emergency rule process.
Under Ohio Revised Code Section 3719.45, the OBP is authorized to add a previously unscheduled compound to Schedule I immediately — bypassing the standard, months-long legislative deliberation, committee hearings, and public comment processes — if the board determines the substance has no accepted medical use and poses an "imminent hazard to the public health, safety, or welfare." On December 12, 2025, the OBP convened a special meeting by telephone conference and unanimously voted to adopt OAC 4729:9-1-01.1, enacting a 180-day emergency ban on mitragynine-related compounds, which DeWine formalized by signing Executive Order 2025-08D.
While the December 2025 emergency order included a textual carveout clarifying that it did not apply to natural kratom in its vegetative form, the administration's ultimate objective remained absolute prohibition. On January 6, 2026, the OBP initiated a separate permanent rulemaking process (OAC 4729:9-1-01.2) specifically designed to classify mitragynine itself — the primary naturally occurring alkaloid in raw kratom leaf — as a Schedule I substance. If enacted, this rule would instantly criminalize the possession, sale, and distribution of all kratom products, transforming a widely utilized botanical supplement into a felony-level narcotic legally equivalent to heroin under Ohio law. (The raw-leaf ban was later shelved by the OBP in July 2026, per Signal Ohio's reporting, while the processed-product ban proceeded through litigation brought by Botanic Tonics and retailer Krazy Daze.)
Reporting also indicates RFK Jr. intervened on Ohio directly: in fall 2025, Kennedy asked DeWine to back off the natural-kratom ban and target only the competing synthetics — stitching the Ohio record directly into the federal conflict-of-interest story.
The DeWine administration's aggressive administrative posture against decentralized, botanical pain management alternatives must be evaluated against the backdrop of its campaign finance profile and state-sponsored economic development strategies. DeWine's career fundraising spans five decades and six offices: his 2018 gubernatorial race alone set an Ohio record at ~$24M, his 2022 re-election raised $31.8M (Ballotpedia/OpenSecrets), and his two attorney-general races added ~$14M — roughly $70M in tracked state races since 2010 alone, before counting his 1990 lieutenant-governor and earlier runs. The report's "$72.4 million over his career" figure is consistent with that record consistent (it matches FollowTheMoney-style career aggregation); his single largest identified backer, however, is the Ohio Republican Party structure (~$4.8M) and himself (~$4.6M self-funded) — the "health/pharma/financial base" characterization remains generic and unverified.
The gambling money, by contrast, is documented to the dollar. An Associated Press investigation (Dec 2022) corroborated found that casino operators, slot-machine makers, gaming-technology companies, and sports-betting interests donated nearly $1 million to the Republican Governors Association between January 2021 and September 2022 — while DeWine, the RGA-backed incumbent and the key decision-maker over Ohio's new $1B sports-betting market, was signing it into law. The RGA then funneled $2.2M+ through its Right Direction PAC into two pro-DeWine committees (Free Ohio PAC, $1.05M; and the Delaware dark-money group Ohioans for Free and Fair Elections, $1.15M). In one instance AP documented, IGT gave to the RGA, which gave to Right Direction, which gave to Free Ohio — all on the same day. Itemized donors include IGT ($320K), Caesars ($250K), the Sports Betting Alliance ($120K), Scientific Games ($75K), Intralot ($75K), and NeoPollard ($25K); industry-tied donors also gave ~$22K directly to DeWine's campaign and ~$130K to state legislators. Of all incumbent GOP governors the RGA was re-electing, DeWine was the only one actively deciding sports-betting policy at the time.
The ideological contradiction becomes stark when examining state subsidies. While the governor claimed kratom constituted an "imminent public health risk" necessitating an emergency ban, his administration simultaneously authorized massive financial incentives for traditional pharmaceutical manufacturers. In June 2026, acting through the Ohio Tax Credit Authority and the Ohio Department of Development, the administration approved Job Creation Tax Credits for Hikma Pharmaceuticals USA Inc.:
| Beneficiary | Location | Scope | Impact | Incentive |
|---|---|---|---|---|
| Hikma Pharmaceuticals | Bedford, OH | Expansion of domestic injectable pharmaceutical manufacturing capacity | 300 FTE positions; $25.5M new annual payroll by 2030 | 1.878%, 15-year Job Creation Tax Credit |
| Hikma Pharmaceuticals | Columbus, OH | Expansion of contract manufacturing and new packaging lines | 50 FTE positions; $3.0M new annual payroll by 2029 | 1.236%, 7-year Job Creation Tax Credit |
The strategic subsidization of a corporate entity deeply entrenched in the traditional pharmaceutical supply chain — while simultaneously utilizing executive fiat to criminalize non-pharmaceutical, unpatented botanical competitors like kratom — highlights a profound structural bias within the Ohio government. The state actively utilizes public funds to protect and expand the commercial dominance of favored healthcare conglomerates, while suppressing alternative, decentralized health markets under the unassailable guise of public safety.
The exact mechanism by which Governor DeWine executed the December 2025 emergency prohibition was the Ohio Board of Pharmacy. During the critical 2025–2026 scheduling actions, the board consisted of nine gubernatorial appointees (eight professional pharmacists and one public member) whose primary livelihoods depend on the dispensation, management, and corporate administration of FDA-approved pharmaceuticals:
| Board member | Role | Professional affiliation |
|---|---|---|
| Jeff Huston, RPh | President / Member | Clinical Professor, Cedarville University; hospital and community pharmacy background. Appointed by DeWine. |
| Mindy Ferris, RPh | Member (Past Pres.) | Former Executive VP of Operations, PharmScript, Inc. (long-term care pharmacy). Appointed by DeWine. |
| Jason George, RPh | Vice President | Supervising Pharmacist, CenterWell Pharmacy; military pharmacy management. Appointed by DeWine. |
| Trina Buettner, RPh | Member | Director of Pharmacy, ProMedica Defiance Regional Hospital. Appointed by DeWine. |
| Tod J. Grimm, RPh | Vice Pres. (FY27) | Pharmacist, Walmart; former President, Ohio Pharmacists Association. Appointed by DeWine. |
| Anthony Buchta, Sr. | Member | Owner, Arena District Pharmacy; past President, Academy of Pharmacy of Central Ohio. Appointed by DeWine. |
| Leonard Hubert | Public Member | Founder/CEO, L Hubert & Associates; former Director, Governor's Office of External Affairs. Appointed by DeWine. |
The unanimous votes cast by this board to implement emergency scheduling must be viewed through the lens of regulatory capture. Members such as Mindy Ferris (PharmScript) and Trina Buettner (ProMedica) operate in highly corporatized sectors — long-term care pharmacy and hospital administration — that rely exclusively on standard pharmaceutical protocols for pain management, anxiety treatment, and opiate withdrawal mitigation. Kratom, explicitly utilized by hundreds of thousands of consumers to self-treat chronic pain, manage anxiety, and mitigate opioid withdrawal symptoms, functions as a direct, untaxed, unpatented market competitor to the therapies dispensed and monetized by the board members' respective employers and professional networks.
The complete absence of representation for chronic pain patients, alternative medicine practitioners, or independent toxicologists on the OBP ensures that all regulatory decisions are filtered exclusively through a rigid pharmacological paradigm — one that views any unpatented, non-FDA-approved botanical substance as dangerous, devoid of medical utility, and requiring immediate criminalization. By utilizing an appointed board comprised entirely of pharmaceutical administrators to ban a botanical competitor, the DeWine administration effectively weaponized the state's police power on behalf of a specific industry.
The OBP's aggressive push to transition the emergency ban on synthetics into a permanent rule, while simultaneously drafting a separate rule to schedule natural mitragynine, provoked severe constitutional friction with the legislative branch. In Ohio, administrative rules must pass through JCARR to ensure the executive agency has not exceeded its statutory authority or bypassed legislative intent.
The JCARR rebuke. On June 22, 2026, JCARR summoned OBP representatives, including Director of Policy Cameron McNamee, to a formal hearing to defend the board's sweeping prohibitions. During this highly contentious hearing, the OBP faced intense bipartisan criticism for attempting an "end run" around the Ohio General Assembly. Representative Jamie Callender directly challenged the board's authority to legislate by fiat:
"I would suggest that it's not the Governor's role either to make policy... We are considering legislation, and have been for a while, maybe slower than we should... But that's the legislative process."
While some lawmakers, such as Representative Sean Brennan, commended DeWine for attempting to protect minors, and Senator Steve Huffman acknowledged the legislature's own inactivity, the overarching sentiment of the hearing highlighted the structural danger of the OBP's tactics: relying on emergency administrative fiat circumvents the democratic process, shielding policy from public testimony, legislative amendment, and direct electoral accountability. Following the hearing, McNamee defensively characterized the clash as mere "differences of opinion," maintaining the board had broken no laws.
Senator Louis "Bill" Blessing III and SB 299. The legislature's parallel effort to establish a statutory framework was primarily spearheaded by Senator Blessing (R-District 8), sponsor of Senate Bill 299, alongside companion House Bill 587. Introduced in late 2025, SB 299 proposed a regulatory compromise heavily favored by the American Kratom Association: (1) strict age limits prohibiting sale to individuals under 18; (2) rigorous testing and labeling standards with product registration through the Ohio Department of Agriculture; and (3) statutory criminalization of high-potency synthetic derivatives — specifically outlawing 7-OH products and chemically altered isolates — treating them distinctly from the natural vegetative leaf.
Who pays for Blessing? His campaign finance is fully public (Transparency USA / Citizens for Blessing, 2024), and it does not show a man bankrolled by pharma or by kratom money. It shows a rank-and-file Senate Republican whose money comes from the party structure, building trades, and realtors — and who, notably, gave away most of his war chest to the Senate Republican caucus:
Blessing is also a genuine, primary sponsor of major healthcare finance reform — SB 386/SB 387 (the "Medicaid Savings Act," moving Ohio Medicaid from MCOs to an ASO model; he cited Connecticut's $4B-over-13-years savings and argued Ohio could save up to $850M a year) and SB 210 (PBM licensing and contract regulation) — all verified on the Ohio Senate's own legislative record. But the honest reading of the combined record is narrower than the original report's insinuation: a healthcare-policy-workhorse senator, funded by his caucus and the building trades, whose kratom bill happened to match what the kratom industry itself was lobbying for. Influence-of-interests is a fair question; a pharma-orchestrated one is not what the receipts show.
To justify the December 2025 emergency order, Governor DeWine and ODH Director Bruce Vanderhoff repeatedly disseminated the claim that synthetic kratom was found to be a cause of death in "more than 200 unintentional overdose deaths in Ohio from 2019 to 2024." This metric demands rigorous methodological deconstruction. In forensic toxicology, mitragynine is frequently identified post-mortem in individuals who have succumbed to severe polysubstance overdoses, primarily involving lethal quantities of illicit fentanyl, heroin, or prescription benzodiazepines. Because kratom is often utilized by individuals actively attempting to self-manage severe opioid use disorder or mitigate fentanyl withdrawal, its presence in a decedent's blood is highly correlated with the presence of deeply lethal, scheduled narcotics.
By aggregating all polysubstance deaths where mitragynine was incidentally detected and publicly attributing the fatality specifically to "synthetic kratom," the state administration generated an artificially inflated risk profile designed to induce public panic. Independent toxicologists and consumer advocacy groups have consistently pointed out that deaths caused exclusively by isolated mitragynine toxicity are exceptionally rare, with public records highlighting that coroners often misattribute fentanyl-driven polysubstance deaths to the presence of kratom. This vital pharmacological nuance is intentionally obfuscated in executive press releases to generate the requisite "imminent hazard" narrative legally required by ORC 3719.45 to justify an emergency rule.
The state further bolstered its narrative by citing a CDC analysis of National Poison Control System data noting a 1,200% increase in kratom-related exposure reports (from 258 to 3,434) leading up to March 2026. However, exposure reports are not equivalent to toxicological fatalities or severe adverse events; they are inquiries, often driven by the very media panic generated by executive press releases.
The rhetorical strategy employed by regulatory agencies involved explicitly branding 7-OH products and concentrated extracts as "gas station heroin." By utilizing this highly emotive terminology, authorities seamlessly conflated the over-the-counter botanical supplement market with the catastrophic, illicit fentanyl crisis. During the JCARR hearings, OBP Director of Policy Cameron McNamee testified using anecdotal, fear-based framing — citing parents who claimed supplements "ruined my life and now I'm in rehab" or expressing fears regarding youth access. This framing was echoed at the federal level by former FDA Commissioner Makary and HHS Secretary Kennedy, who described 7-OH derivatives as driving the "next wave of the opioid crisis."
Notably, Legis1's lobbying-records reporting identified "Stop Gas Station Heroin LLC" as an astroturf operation funded by Botanic Tonics allies corroborated — meaning the fear framing itself was partly manufactured by one kratom company to kill its competitors. The slogan Ohio and the feds leaned on was, in part, industry war-propaganda rather than public health messaging. This rhetorical bridge allowed the OBP to pivot smoothly from banning synthetics under the guise of the "gas station heroin" panic in December 2025 to proposing a total, absolute ban on the natural plant itself in January 2026.
The framing that dominated this policy fight — addiction, diversion, "opioid-dependent populations" — systematically erases the people actually keeping this market alive: chronic pain patients the medical system has already failed. Roughly one in four U.S. adults lives with chronic pain (CDC, 2023). For a large share of them, the formal system offers nothing: decades of escalating scheduling pressure, prescription-drug monitoring, and prosecutor-led campaigns against prescribers have primed doctors to treat empathy as a liability. Patients who once received adequate opioids report being force-tapered to doses that leave them bedridden, or cut off entirely; the pain community's own literature documents patients deteriorating — and in documented cases dying by suicide — after losing access to treatment. That is the environment in which kratom, and concentrated 7-OH above all, found its audience: for people with severe, opioid-responsive pain and no willing prescriber, it presented the only known safe potent opioid option — effective analgesia through the G-protein-biased pathway, obtainable without a gatekeeper who has been scared out of saying yes.
That is what emergency scheduling actually eliminates. Not a street drug — a last resort. Prohibition does not distinguish the dependent user from the bedridden one; a felony schedule removes the safe option from both. Dependence is real and deserves honest treatment — regular users do develop withdrawal, and products engineered for maximum punch carry real risk of it — but the policy response on the table is to take the one potent opioid with a raised therapeutic window and effectively zero confirmed sole-cause deaths, and make its possession a felony, while the prescriptions that were never available to these patients in the first place remain legally sacred. The harm-reduction and MAT-funnel consequences below are real, but they are the second-order story. The first-order story is millions of pain patients for whom the choices were: untreated suffering, this, or the illicit market — and the state has now criminalized choice two on the theory that it was protecting them from themselves.
The testimonies back this reading. Kratom consumers and small business owners in Ohio didn't warn about withdrawal economics — they warned about people: "Take kratom away. People are going to find something much worse." The medical establishment's formalized alternative is to route the displaced into medication-assisted treatment (buprenorphine/naloxone) — a therapy that requires exactly the prescriber attention these patients could never obtain, and which monetizes their pain for the same industry whose lobbying baseline this report has already charted.
Historically, prohibition of psychoactive substances does not eliminate consumer demand; it shifts the supply chain into the illicit sector. The scheduling of 7-OH and mitragynine pseudoindoxyl ensures the rapid development of an unregulated, dangerous black market, with clandestine chemists stripping away all quality control. Furthermore, as demonstrated by the DEA's proactive scheduling of MGM-15 and MGM-16, the chemical arms race has already begun: banning one synthetic derivative financially incentivizes rogue manufacturers to synthesize entirely new analogs — such as the 9-fluoro derivatives specifically targeted by the DEA — that temporarily bypass the rigid molecular definitions of the ban, perpetuating an endless cycle of reactionary scheduling.
The coordinated campaign to schedule 7-hydroxymitragynine and baseline mitragynine represents a sophisticated convergence of federal agency action, state-level executive overreach, and deep-seated pharmaceutical industry influence. At the federal level, the DEA and FDA's threshold-based prohibition mechanisms are overshadowed by a congressional corruption probe alleging that the very officials dictating policy possess deep, million-dollar financial conflicts of interest, operating in tandem with Big Tobacco and specialized lobbying firms.
In Ohio, the DeWine administration's aggressive use of emergency administrative powers to bypass legislative deliberation stands as a premier example of regulatory capture. By utilizing a Board of Pharmacy composed entirely of professionals structurally entrenched in the conventional medical supply chain, the state outlawed an over-the-counter botanical competitor under the guise of a manufactured public health crisis — concurrently with awarding tens of millions in tax incentives to pharmaceutical manufacturers like Hikma.
The deepest failure here is a policy architecture that treats every consumer as a suspect. Over-harsh scheduling has already hollowed out clinical empathy for pain patients — prescribers now ration compassion by legal fear — and these emergency rules apply the same logic to the one potent opioid those abandoned patients could still reach. A sane framework starts from medical necessity: honest potency and dependence labeling, adult-only sale, contaminant testing — the consumer-protection floor that statutory bills like SB 299 gestured at — while protecting, not criminalizing, access for the chronic pain population medicine has left behind. Without that inversion, emergency scheduling will keep doing what it has already done here: protect corporate pharmaceutical monopolies, criminalize the untreated, and hand the remaining demand to the illicit market.